Products / Oncology and Oncohematology

Fontrax

Dasatinib 50-100 mg

Dasatinib is indicated for the treatment of chronic myelogenous leukemia and Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL).

Therapeutic Action

Antineoplastic

Presentation

Fontrax 50: 60 tablets

Download Prospect

Fontrax 100: 30 tablets

Download Prospect
This pharmaceutical product is gluten free. Suitable for celiacs.
This product is subject to a Risk Management Plan (PGR) approved by ANMAT.

More information:
farmacovigilancia@richmondlab.com
Fontrax Dasatinib 50-100 mg de Laboratorios Richmond

Legal Notice

Products which continue to have a valid patent protection at present are manufactured in line with the current laws of the Argentine Republic. Please, take into account that our products will only be shipped to countries where the substance and its use are not protected by patents.

Laboratorios Richmond S.A.C.I.F. Argentina © All rights reserved Terms of use Privacy policy

NOTICE The legal content included on this site was designed exclusively to meet the needs of the health-care professionals for the adequate use of the pharmaceutical products. It does not contain promotional information. All the texts referring to our prescription products are compliant with the guidelines approved by ANMAT, the Argentine administration for drugs, food and medical technology. Laboratorios Richmond always recommends consulting a qualified health-care professional if you have doubts regarding any given medical

I understand and wish to see the information